Abstract
There is now compelling evidence that stem cells can be used as gene therapy delivery cells. Stem cells isolated from the Wharton’s jelly of the umbilical cord (termed Wharton’s jelly stromal cells) can be harvested noninvasively in large numbers and have been shown to traffic to tumors but do not form tumors themselves. WJS cells have low immunogenicity and they have also been engineered to secrete a cytokine, shown to home locally into the tumors in mice and with subsequent tumor attenuation. Naive rat and human Wharton’s jelly stromal cells that are not engineered to secrete an exogenous protein also exert a potent anticancer effect in preclinical models.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.